Edit

AMR Action Fund

https://www.amractionfund.com

Last activity: 12.08.2026

Active

Invests in categories: AntibioticsBiotechBiotechnologyDevelopmentFinTechHealthcareHealthTechMedTechPharmaTherapeutics

Aiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.

Portfolio

Mentions

Investment Stage: Series A

Twitter

Portfolio 14

Date	Name	Website	Total Raised	Location
11.08.2026	Vedanta Bi...	vedantabio.com	$333.9M	United Sta...
02.08.2026	Trellis Bi...	trellisbio.com	$10M	United Sta...
06.07.2026	Telum Ther...	telumtherapeutics.com	$25.25M	Spain
24.02.2026	Centauri T...	centauritherapeutics.com	$50.12M	United Kin...
16.10.2025	Peptilogic...	peptilogics.com	$118.9M	United Sta...
-	BioVersys ...	bioversys.com	$186.89M	Switzerlan...
-		eliontx.com	-	-
-	Venatorx P...	venatorx.com	$42M	United Sta...
-	BiomX Inc	biomx.com	$56M	Israel, Ce...
-	ANTABIO	antabio.com	$63.53M	France, Oc...
-	TenNor The...	tennorx.com	-	China, Gan...
-	F2G	f2g.com	$291M	United Kin...
-	Pattern Bi...	pattern.bio	$51M	United Sta...
-		utilitytherapeutics.com	-	United Kin...

Mentions in press and media 25

Date	Title	Description
12.08.2026	Vedanta Biosciences Secures $60M for Groundbreaking Microbiome Therapy	Vedanta Biosciences secured $60 million in new capital. The Cambridge, MA biopharma advances microbiome-based oral therapies. Funds fuel its pivotal Phase 3 RESTORATiVE303 study. This trial targets recurrent C. difficile infection. Investor...
11.08.2026	Vedanta Biosciences Nabs $60M Financing Round	CAMBRIDGE, MA, Vedanta Biosciences has secured $60 million in funding. >> Click here for more funding data on Vedanta Biosciences >> To export Vedanta Biosciences funding data to PDF and Excel, click here Vedanta Biosciences, a...
06.08.2026	Vedanta Biosciences Raises $60M in Funding	Vedanta Biosciences, a Cambridge, MA-based provider of microbiome-based oral therapies for gastrointestinal diseases, raised $60M in funding. The round was led by AMR Action Fund and BNP Paribas Asset Management Alts, with participation fro...
20.07.2026	Trellis Bioscience Raises $9 Million Series C To Advance Calpurbatug For Prosthetic Joint Infections	Trellis Bioscience has raised $9 million in Series C funding to support the clinical development of calpurbatug, also known as TRL1068. The investigational monoclonal antibody is being evaluated as a treatment for chronic prosthetic joint i...
17.07.2026	CDTI compromete 20,8 millones en siete empresas y hasta 75 millones en un fondo de Suma Capital	CDTI Innovación, a través de Innvierte, cerró durante junio siete operaciones de coinversión por un importe conjunto de 20,8 millones de euros. Las compañías respaldadas desarrollan soluciones en ámbitos como la biotecnología, la salud, el ...
17.07.2026	Trellis Bioscience Closes $9M Series C	REDWOOD CITY, CA, Trellis Bioscience has announced the closing of a $9 million Series C financing. >> Click here for more funding data on Trellis Bioscience >> To export Trellis Bioscience funding data to PDF and Excel, click h...
06.07.2026	Telum Therapeutics Raises €18 Million Series A To Advance Antimicrobial Program	Telum Therapeutics announced the completion of an €18 million Series A financing round. The funding will advance the company’s lead antimicrobial program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pn...
24.02.2026	Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate	Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections Investment from the world’s largest venture capital fund focused exclusively on a...
18.10.2025	Peptilogics Secures $78M to Advance Breakthrough PJI Therapy Zaloganan	Peptilogics, a clinical-stage biotechnology firm, closed an oversubscribed $78 million Series B2 funding round. This capital propels zaloganan (PLG0206), its lead candidate, toward a pivotal Phase 2/3 clinical trial. Zaloganan targets prost...
16.10.2025	Peptilogics: $78 Million Raised For Advancing Zaloganan Toward Pivotal Trial For Prosthetic Joint Infections	Peptilogics, a clinical-stage biotechnology company pioneering surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round. The funding round was led by Presight Capital, Thiel Bio...
16.10.2025	Peptilogics Raises $78M in Series B2 Funding	Peptilogics, a Pittsburgh, PA-based clinical-stage biotechnology company developing surgical therapeutics to effectively treat and prevent serious medical device infections, closed a $78m Series B2 financing round. Presight Capital, Thiel B...
29.01.2025	BioVersys to go public next week	BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced toda...
29.01.2025	BioVersys sets IPO price at CHF 36.00 per share ahead of SIX Swiss Exchange debut	"As a scientific founder, the educational programs organized and co-organized by Venturelab, such as the SIX IPO Academy, provide very valuable toolboxes that you need during your entrepreneurial path," Marc Gitzinger, Co-Founder ...
21.01.2025	BioVersys to go public at SIX Swiss Exchange	BioVersys’ two clinical programs address life-threatening antibiotic resistant bacterial infections, focusing on profitable indications within the antibiotic space, in pneumonia, blood stream infections and meningitis. BioVersys’ two clini...
24.09.2024	Health \| Drug-resistant germs will kill millions more people in coming decades, researchers warn	It was released in advance of a United Nations General Assembly meeting later this month on drug-resistant pathogens. “The numbers in the Lancet paper represent a staggering and unacceptable level of human suffering,” said Henry Skinner, ch...
18.05.2024	Health \| A mother’s loss launches a global effort to fight antibiotic resistance	“Diary Of A Dying Girl” excerpts Mallory Smith’s own writings, which chronicle her 13-year battle against an antibiotic-resistant lung infection. (Genaro Molina/Los Angeles Times/TNS) On Tuesday, Random House published “Diary of a Dying Gir...
06.01.2023	Boston's Action Fund for antimicrobial resistance has closed its first European deal, pouring funds into Swiss biotech BioVersys	AMR Action Fund, a bacterial resistance-themed investment vehicle armed with $1 billion to spend, has backed a series C round for BioVersys, a developer of antimicrobial products based out of Basel, Switzerland. BioVersys's series C has now...
05.01.2023	AMR Action Fund Announces Investment in BioVersys AG	Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership inve...
05.01.2023	BioVersys secures an additional CHF 8.4 million to advance clinical studies
03.03.2021	The Biden administration’s pandemic agenda must not ignore superbugs	What if another devastating pandemic came on the heels of Covid-19? Unfortunately, that looks increasingly possible. For years, the antibiotics used to fight various bacterial infections have grown gradually less effective. If current trend...
11.01.2021	Can we warp-speed antibiotic development?	Now, advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis. They have been working together to address it under wide-ranging federal guidance issued in March 2015, titled the “U.S. Na...
12.08.2020	We need new antimicrobials to prevent the next infectious disease crisis	Imagine if scientists had seen Covid-19 coming years in advance yet did little to prepare. Unthinkable, right? Yet that’s exactly what’s happening with another infectious disease crisis — the one caused by antibiotic-resistant bacteria and ...
04.08.2020	Could Drug-Resistant Bacteria Cause The Next Pandemic?	Venetians dressed as plague doctors pose during Carnival in their city's Piazza San Marco on ... [+] February 25, 2020. Their costume dates to the Italian Plague of 1629–1631. (Photo by Giacomo Cosua/NurPhoto via Getty Images)NurPhoto via G...
09.07.2020	Two dozen big drug makers launch a $1 billion fund to develop new antibiotics	In response to heightened concerns over antibiotic resistance, two dozen of the world’s largest pharmaceutical companies have formally launched a $1 billion for-profit venture fund to replenish the global medicine chest with novel treatment...
-	Can we warp-speed antibiotic development?	While doctors scramble to understand the viral illness Covid-19, bacteria pose no small threat, especially given increasing antibiotic resistance and prevalence of superbugs. Medical centers rely on antibiotics to treat everything from post...

AMR Action Fund

Portfolio 14

Mentions in press and media 25

Reviews 0